Clinical trials: IBM
IBM, Inclusion Body Myositis
Imaging Assessment of Swallowing and Speech Muscles in Inclusion Body Myositis
This study will evaluate whether neuromuscular ultrasound and MRI can be used as imaging markers of bulbar involvement and swallowing dysfunction in individuals with inclusion body myositis (IBM).
- Conditions
- IBM, Inclusion Body Myositis, Myopathy, Myositis
- Trial name
- NCT07823101
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Inclusion Body Myositis (IBM), Motor Neuron Disease, Amyotrophic Lateral Sclerosis
The Aim of the Study is to Characterize Patients Exhibiting Muscular Atrophy and Weakness Who Require a Muscle Biopsy for Diagnosis (IBM vs Atypical MND), Through an Innovative Technique Which Enables the Evaluation of the Neuromuscular Junction Involvement in Each Condition
The aim of the study is to characterize 30 patients exhibiting muscular atrophy and weakness who require a muscle biopsy for diagnosis (suspected inclusion body myopathy vs atypical motor neuron disease), through an innovative…
- Trial name
- TDP-signatures (NCT07796776)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- IRCCS San Raffaele
IBM, IIM
MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
Myositis diseases are each rare diseases. As in other rare diseases, people living with myositis diseases face physical and psychosocial challenges that may not be recognized in current research priorities.
- Conditions
- IBM, IIM, Myositis, Inflammatory Myopathy
- Trial name
- MIHRA-PRISMS (NCT07374107)
- Testing
- No intervention - qualitative and mixed methods investigations
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Myositis International Health & Research Collaborative Alliance Foundation
Inclusion Body Myositis (IBM)
Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis
Sporadic Inclusion Body Myositis (IBM) is the most frequent inflammatory myopathy in patients over 50. It is a slowly progressive, but today untreatable (notably by classical immunosuppressants) disease.
- Trial name
- RAPAMI (NCT02481453)
- Testing
- Rapamycin
- Where
- France
- Volunteers
- 44 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Inclusion Body Myositis (IBM)
Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis
ABC008-IBM-202 is an open-label, multicenter study to evaluate the safety and efficacy of long-term administration of ulviprubart (ABC008) in subjects with IBM who have completed either Study ABC008-IBM-101 or Study…
- Trial name
- NCT06450886
- Testing
- Ulviprubart (ABC008)
- Where
- 21 sites in United States, Australia
- Volunteers
- 270 people
- Sponsor
- Abcuro, Inc.
Inclusion Body Myositis (IBM), Feasibility Study
Exercise as Treatment for Patients With Inclusion Body Myositis
There is little knowledge about exercise for patients with inclusion body myositis (IBM). Patients with IBM have limited access to rehabilitation and physiotherapy resources, despite a significant need for these services due to…
- Trial name
- NCT06644482
- Testing
- Exercise group in a hospital setting
- Where
- Norway
- Volunteers
- 15 people
- Sponsor
- Oslo University Hospital
IBM, Inclusion Body Myositis
Establishing Muscle Impedance Parameters With Electrical Impedance Myography
The primary aim of this study is to assess the changes in the impedance parameters of muscles in inclusion body myositis (IBM) through electrical impedance myography (EIM), an emerging non-invasive electrodiagnostic technology.
- Trial name
- NCT03633318
- Testing
- electrical impedance myography (EIM)
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Yale University
Inclusion Body Myositis (IBM)
Natalizumab in Inclusion Body Myositis (IBM)
Muscle biopsies of patients with Inclusion Body Myositis (IBM) have demonstrated a T-cell predominant inflammatory infiltrate, therefore, new agents targeting T -cell mediated cell death may be a novel treatment for IBM.
- Trial name
- IBM-NAT (NCT02483845)
- Testing
- Natalizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Phoenix Neurological Associates, LTD